Virtual Library

Start Your Search

A. Wolf



Author of

  • +

    MINI 19 - Surgical Topics in Localized NSCLC (ID 138)

    • Event: WCLC 2015
    • Type: Mini Oral
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      MINI19.14 - Survival After Sub-Lobar Resection for Early Stage Lung Cancer: Methodological Obstacles in Comparing the Efficacy to Lobectomy (ID 1583)

      16:45 - 18:15  |  Author(s): A. Wolf

      • Abstract
      • Presentation
      • Slides

      Background:
      Surgery is the treatment of choice for early stage lung cancer (LC). While lobectomy (L) is the historic standard, whether long term outcomes of sub-lobar resection (SL) are comparable is still under debate. The only randomized trial was conducted 20 years ago; 5 subsequent meta-analyses showed inconclusive or conflicting results. We present a comprehensive review of the literature on 5 year-survival after SL compared to L for early stage LC.

      Methods:
      A priori inclusion criteria were: 1) observational studies, 2) L compared to SL for early stage LC, 3) at least CT staging, 4) 5-year survival reported. A Medline search through January 2015 resulted in 32 studies, representing 24 distinct datasets. The absolute difference in 5-year survival was calculated and plotted for each study.

      Results:
      There were 4,702 cases treated with L, 2,323 treated with SL. Of 20 studies reporting the reason for SL, 11 indicated that SL was performed because of comorbidities, or impaired cardiopulmonary function. Among all 24 studies, 4 showed no difference in 5-year survival, 13 favored L, and 7 favored SL (Figure 1). Of the two studies using propensity scores, one favored L and the other SL. No meta-estimate could be calculated due to high statistical heterogeneity. Of 21 studies reporting recurrence rate (Figure 2), 11 favored L and 10 favored SL. Figure 1



      Conclusion:
      Studies comparing 5-year survival rates of SL to L are heterogeneous, and traditional meta-analytic summary estimates of survival and recurrence could not be calculated. SL survival is often similar to L survival, despite the fact that SL is performed in patients with comorbidities or impaired cardiopulmonary function. New approaches to comparing L to SL survival are needed.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    MINI 38 - Biology and Prognosis (ID 167)

    • Event: WCLC 2015
    • Type: Mini Oral
    • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
    • Presentations: 1
    • +

      MINI38.14 - Surgery and Not Radiation Improves Survival in Malignant Pleural Mesothelioma (ID 3168)

      18:30 - 20:00  |  Author(s): A. Wolf

      • Abstract
      • Presentation

      Background:
      Surgery has a controversial role in the treatment of malignant pleural mesothelioma (MPM) as no trial has demonstrated independent survival benefit of surgery. Likewise, there is lack of consensus regarding the role of radiation in MPM. We evaluated whether cancer-directed surgery and/or radiation independently influenced MPM survival in a large population-based dataset.

      Methods:
      The Surveillance, Epidemiology, and End Results database was explored from 1973 to 2009 to identify all cases of pathologically-proven MPM. Age, sex, race, diagnosis year, stage, cancer-directed surgery, radiation, and vital status were analyzed (chemotherapy data not available). The association between prognostic factors and survival was estimated using a Cox proportional hazards model.

      Results:
      There were 14,228 patients with pathologic diagnosis of MPM. On multivariable analysis, female gender, younger age, localized stage, and cancer-directed surgery were independently associated with longer survival (Table). Survival was longer for patients who underwent surgery or surgery and radiation but not for those who underwent radiation only (Figure).

      Table. Association between Patient and Disease Characteristics and Survival
      Variable Category Adjusted HR (95% CI) *
      Sex Male 1 (Ref)
      Female 0.78 ( 0.75-0.82)
      Race White 1 (ref)
      Black 1.07 (0.98-1.16)
      Other 0.99 (0.89-1.09)
      Age (years) continuous 1.24 (1.22-1.26)
      Stage Localized 1 (ref)
      Regional 1.30 (1.21-1.40)
      Distant 1.34 (1.26-1.42)
      Diagnosis year 1973-1989 1 (ref)
      1990-1994 0.91 (0.85-0.97)
      1995-1999 0.86 (0.81-0.92)
      2000-2004 0.86 (0.81-0.91)
      2005-2009 0.80 (0.75-0.84)
      Therapy No radiation or surgery 1 (ref)
      Radiation only 1.17 (1.10-1.25)
      Surgery only 0.65 (0.62-0.68)
      Radiation and surgery 0.69 (0.63-0.75)
      Figure 1



      Conclusion:
      In this study of 14,228 patients over 36 years, cancer-directed surgery was associated with better survival in MPM, independent of other forms of therapy, including radiation. These data support the role of surgery-based therapy as the cornerstone for treatment in this challenging disease.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

  • +

    P2.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 225)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
    • Presentations: 1
    • +

      P2.08-017 - Chest Wall Soft Tissue Sarcomas: Impact of Adjuvant Radiation Therapy Following Surgical Resection (ID 1587)

      09:30 - 17:00  |  Author(s): A. Wolf

      • Abstract
      • Slides

      Background:
      Primary chest wall soft tissue sarcomas are rare tumors of the thoracic wall. The objective of this study is to evaluate the impact of adjuvant radiation therapy on survival following surgical resection using the Surveillance, Epidemiology, and End Results (SEER) database.

      Methods:
      We queried the SEER database for all surgically resected histologically proven primary chest wall soft tissue sarcomas between 1998 and 2010. Exclusion criteria included pediatric sarcomas, multiple malignancies and unknown grade, stage or radiation therapy status. Chi-square tests were performed to identify covariates associated with receiving adjuvant radiation therapy. Coarsened-exact matching was used to generate a matched cohort of patients who received adjuvant radiation following surgery and patients who underwent surgery alone. Cox regression and Kaplan-Meier analyses were performed to determine covariates associated with overall survival.

      Results:
      A total of 570 patients were included in the cohort prior to matching based on the selection criteria. Histological type (p = 0.003) and tumor grade (p < 0.001) were independently associated with receiving radiation therapy. Cox-regression did not demonstrate reduced hazards of death for adjuvant RT. After coarsened-exact matching, Kaplan-Meier survival analysis of matched groups (105 surgery alone and 104 surgery + RT) showed significant 1-, 3- and 5-year overall survival difference (p = 0.034) in surgery + RT compared to surgery alone.

      Conclusion:
      In a matched large population cohort, adjuvant radiation therapy appears to improve overall survival following surgical resection of chest wall soft tissue sarcomas. Further trials are required to determine the efficacy of adjuvant radiation therapy in this population.Figure 1



      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.02 - Poster Session/ Treatment of Localized Disease – NSCLC (ID 211)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Localized Disease - NSCLC
    • Presentations: 1
    • +

      P3.02-005 - Third Primary Lung Cancers: Incidence and Benefits of Surgical Therapy (ID 1688)

      09:30 - 17:00  |  Author(s): A. Wolf

      • Abstract
      • Slides

      Background:
      Continued surveillance of lung cancer patients after curative surgery allows for the diagnosis of new disease. However, there is a relative paucity of data in regards to the development of third primary lung cancers. The goals of this study were to examine the incidence of third primary cancers and the results of surgical therapy.

      Methods:
      Surgically resected Stage 1 second primary lung cancers with complete data were identified in The Survival Epidemiology and End Results (SEER) database between 2004 and 2010. Among these 238 cases, those which developed a third primary lung cancer 6 or more months after the diagnosis of the second primary were analyzed. Statistical methods were performed using Kaplan-Meier and multivariate analysis. A p value < 0.05 was considered statistically considered significant.

      Results:
      Twenty-four patients (10.1%) experienced a third primary lung cancer; sixteen cases (66.7%) were diagnosed in stage I. Twelve patients (50% of cases) underwent cancer surgery. Nine patients (37.5%) were treated with beam radiation – alone (8 cases, 89%) or in combination with surgery (1 case, 11%). Surgery was performed more frequently in early stages (75% of surgical cases were stage I versus 58% of non-surgical cases). There was no difference in age between patients who underwent any treatment and those who did not. Length of follow-up in third primary cancers was 18 months if surgically treated and 8 months if not surgically treated (p < 0.02). At multivariate analysis, the only independent predictor of improved survival was treatment (Hazard ratio (HR) 0.21, 95% CI: 0.07-0.66; p=0.007). Both surgery (HR=0.02; 95% CI: 0.002-0.29) and radiation (HR= 0.04; 95% CI: 0.002-0.54) significantly improved survival. Figure 1



      Conclusion:
      The overall incidence of third primary lung cancers after a second primary is 10.1%. Surveillance and intervention at early stage results in improved survival.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.